These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 38895182)
1. A review of MASLD-related hepatocellular carcinoma: progress in pathogenesis, early detection, and therapeutic interventions. Ma Y; Wang J; Xiao W; Fan X Front Med (Lausanne); 2024; 11():1410668. PubMed ID: 38895182 [TBL] [Abstract][Full Text] [Related]
2. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma. Wang Y; Fleishman JS; Li T; Li Y; Ren Z; Chen J; Ding M Front Pharmacol; 2023; 14():1336216. PubMed ID: 38313077 [TBL] [Abstract][Full Text] [Related]
3. Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma. Rivera-Esteban J; Muñoz-Martínez S; Higuera M; Sena E; Bermúdez-Ramos M; Bañares J; Martínez-Gomez M; Cusidó MS; Jiménez-Masip A; Francque SM; Tacke F; Minguez B; Pericàs JM Clin Gastroenterol Hepatol; 2024 Sep; 22(9):1774-1789.e8. PubMed ID: 38604295 [TBL] [Abstract][Full Text] [Related]
4. MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options. Shi Y; Taherifard E; Saeed A; Saeed A Curr Issues Mol Biol; 2024 Jun; 46(6):5965-5983. PubMed ID: 38921027 [TBL] [Abstract][Full Text] [Related]
5. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study. Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992 [TBL] [Abstract][Full Text] [Related]
7. Modifiable Risk Factors for Hepatocellular Carcinoma in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis. Xiao S; Liu Y; Fu X; Chen T; Xie W Am J Med; 2024 Jul; ():. PubMed ID: 39047929 [TBL] [Abstract][Full Text] [Related]
8. Metabolic dysfunction-associated steatotic liver disease has become the most common cause of hepatocellular carcinoma in Sweden: A nationwide cohort study. Vaz J; Jepsen P; Strömberg U; Midlöv P; Eriksson B; Buchebner D; Hagström H Int J Cancer; 2024 Jul; ():. PubMed ID: 39016032 [TBL] [Abstract][Full Text] [Related]
9. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary. ; ; Diabetologia; 2024 Jun; ():. PubMed ID: 38869512 [TBL] [Abstract][Full Text] [Related]
10. Metabolic dysfunction-associated steatotic liver disease increases hepatocellular carcinoma risk in chronic hepatitis B patients: a retrospective cohort study. Lin M; Gao B; Peng M; Chen X; Xiao H; Shi M; Zhang X; Zeng F; Chi X Front Physiol; 2024; 15():1347459. PubMed ID: 38405121 [No Abstract] [Full Text] [Related]
12. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis. Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Casalino A; Bocca C; Novo E; Protopapa F; Ramavath NN; Provera A; Gambella A; Bugianesi E; Tacke F; Albano E; Parola M Front Immunol; 2024; 15():1342404. PubMed ID: 38469298 [TBL] [Abstract][Full Text] [Related]
13. Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma. Ha S; Wong VW; Zhang X; Yu J Gut; 2024 Jun; ():. PubMed ID: 38950910 [TBL] [Abstract][Full Text] [Related]
14. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). ; ; ; J Hepatol; 2024 Sep; 81(3):492-542. PubMed ID: 38851997 [TBL] [Abstract][Full Text] [Related]
15. Association between Metabolic-Dysfunction-Associated Steatotic Liver Disease and Hepatic Cancer: Current Concepts and Future Challenges. Bader H; Yamin S; Alshahwan H; Farraj H; Maghnam J; Abu Omar Y J Clin Med; 2024 May; 13(11):. PubMed ID: 38892843 [No Abstract] [Full Text] [Related]
16. Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study. Yun B; Park H; Ahn SH; Oh J; Kim BK; Yoon JH Am J Gastroenterol; 2024 Jun; ():. PubMed ID: 38934496 [TBL] [Abstract][Full Text] [Related]
17. MASLD-Related HCC-Update on Pathogenesis and Current Treatment Options. Leyh C; Coombes JD; Schmidt HH; Canbay A; Manka PP; Best J J Pers Med; 2024 Mar; 14(4):. PubMed ID: 38672997 [TBL] [Abstract][Full Text] [Related]
18. Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin. Meroni M; Longo M; Dongiovanni P Front Endocrinol (Lausanne); 2024; 15():1411706. PubMed ID: 38846491 [TBL] [Abstract][Full Text] [Related]
19. Chronic Viral Hepatitis B and C Outweigh MASLD in the Associated Risk of Cirrhosis and HCC. Lee MH; Chen YT; Huang YH; Lu SN; Yang TH; Huang JF; Yin SC; Yeh ML; Huang CF; Dai CY; Chuang WL; Yu ML; Yang HI; Chen HY; Chen CJ Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1275-1285.e2. PubMed ID: 38365094 [TBL] [Abstract][Full Text] [Related]